[144] Iron Mountain Inc. SEC Filing

Rhea-AI Filing Summary

Barclays PLC (BCS) filed a Form 6-K containing 25 separate Regulatory News Service (RNS) exhibits covering: (i) daily progress on the 2025 share-buy-back programme announced on 14 February 2025, (ii) monthly total-voting-rights disclosure, and (iii) multiple notifications of dealings by persons discharging managerial responsibility (PDMRs).

Share-buy-back highlights

• Between 30 May 2025 and 25 June 2025 the bank repurchased 47.4 million ordinary shares for cancellation at prices between 317.05p and 334.10p, reducing the issued capital from 14,229,471,353 to 14,182,099,898 shares (-0.33%).
• Since programme launch (14 Feb 2025) Barclays has bought back 266,188,377 shares, equivalent to c.1.9 % of the starting share count, at a volume-weighted average price of 301.39p, spending roughly £0.80 bn.
• No shares are held in treasury; all repurchased stock has been cancelled, improving per-share metrics.

Total voting rights as at 31 May 2025 stand at 14,229,471,353; subsequent cancellations (above) will flow into the June month-end denominator.

PDMR transactions

• Routine quarterly fixed-remuneration share deliveries to 14 senior executives (price £3.256) plus immediate sales to cover tax.
• CEO C.S. Venkatakrishnan and CFO Anna Cross each received new Long-Term Incentive Plan (LTIP) conditional awards over 3.12 m and 1.70 m shares respectively (strike price reference £2.799; vesting 5 tranches over 7 years).
• A clerical correction was issued for Taylor Wright’s earlier disclosure; the underlying data were unchanged.

No earnings, guidance or financing updates are included; the filing is strictly administrative, evidencing capital-return execution and governance transparency.

Positive

• 266 million shares repurchased since 14 Feb 2025 (≈1.9 % of outstanding), signalling capital strength and enhancing EPS.
• All repurchased shares cancelled, providing immediate per-share accretion with no treasury overhang.
• Transparent, timely PDMR disclosures and swift correction of an error support strong governance reputation.

Negative

• Large LTIP awards (≈4.8 m shares) introduce future dilution, partially offsetting buy-back benefits.
• Buy-backs absorb regulatory capital; if earnings weaken, potential pressure on CET1 could arise.

Insights

Equity Research Analyst

TL;DR Ongoing buy-backs retire 1.9 % of shares YTD, mildly accretive; no fundamental earnings data disclosed.

Barclays has accelerated its 2025 £1 bn buy-back, cancelling ~266 m shares at an average 301p, equivalent to ~45 bp of CET1 consumption. At the current pace (~11.5 m shares/day) the programme should conclude around late July, supporting EPS and ROE optics ahead of H1 results. The narrow trading range (323-334p) suggests disciplined execution but offers limited insight into underlying operating trends. Absence of treasury shares means full cancellation benefit feeds through immediately. Executive LTIP grants create future potential dilution but are small (<0.3 % of share capital) and substantially offset by the repurchases. Overall, the filing is modestly positive for shareholders and neutral for credit investors.

Corporate Governance Specialist

TL;DR Disclosures show strong compliance; minor correction highlights data-integrity vigilance.

The volume of PDMR notifications underscores Barclays’ adherence to MAR and FCA transparency rules. Quarterly share payments and associated tax sales are routine under the bank’s fixed-pay framework, aligning management with equity performance while deferring true ownership via five-year holding periods. The LTIP awards to the CEO/CFO follow prevailing UK banking pay norms and are subject to long-term performance tests, mitigating short-term risk incentives. The correction to Taylor Wright’s sale date, issued within 24 hours, indicates robust control effectiveness. No red flags emerge regarding insider dealing or excessive dilution.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	6000	612120.00	295043896	07/01/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/01/2025	Restricted Stock Vesting	Issuer			6000	03/01/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Barclays (BCS) shares have been repurchased in 2025 so far?

As of 24 June 2025, 266,188,377 ordinary shares have been bought back and cancelled.

What is Barclays’ current issued share capital after the cancellations?

Following the 25 June 2025 cancellation, issued share capital is 14,182,099,898 ordinary shares.

At what average price is Barclays executing the 2025 buy-back?

The volume-weighted average purchase price to date is 301.39p per share.

Did Barclays place the repurchased shares in treasury?

No. All shares were cancelled; Barclays holds zero treasury shares.

What executive share awards were disclosed in this 6-K?

CEO Venkatakrishnan received 3.12 m conditional LTIP shares; CFO Cross received 1.70 m; 14 executives received smaller fixed-pay share tranches.

Why was a correction issued on 25 June 2025?

An incorrect transaction date in Taylor Wright’s PDMR sale was amended; all other data remained unchanged.